Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Current Leases (2022 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Current Leases for 4 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 2.5% year-over-year to $6.2 million, compared with a TTM value of $6.2 million through Dec 2025, up 2.5%, and an annual FY2025 reading of $6.2 million, up 2.5% over the prior year.
  • Current Leases was $6.2 million for Q4 2025 at Xeris Biopharma Holdings, up from $6.2 million in the prior quarter.
  • Across five years, Current Leases topped out at $6.2 million in Q4 2025 and bottomed at $1.4 million in Q1 2023.
  • Average Current Leases over 4 years is $4.4 million, with a median of $5.3 million recorded in 2024.
  • The sharpest move saw Current Leases surged 219.34% in 2024, then grew 2.5% in 2025.
  • Year by year, Current Leases stood at $1.6 million in 2022, then soared by 121.2% to $3.5 million in 2023, then soared by 73.96% to $6.1 million in 2024, then grew by 2.5% to $6.2 million in 2025.
  • Business Quant data shows Current Leases for XERS at $6.2 million in Q4 2025, $6.2 million in Q3 2025, and $6.2 million in Q2 2025.